



University
of Basel

Faculty of
Medicine



The Vital Role of Patients in Shaping Drug Development

Continuing Education Series:
Frontiers in Drug Development

Biozentrum,
Spitalstrasse 41,
4056 Basel
Thursday, September 5, 2024
08:30 – 16:15

ECPM[®] 
European Center of Pharmaceutical Medicine

CONTINUING
EDUCATION

Under the auspices of
EUCOR, the European Campus
IFAPP, Int. Federation of Associations of Pharmaceutical Physicians
and Pharmaceutical Medicine

Accredited by SwAPP/SGPM and FPH SPITAL
Recognized as PharmaTrain Centre of Excellence



Invitation

The Vital Role of Patients in Shaping Drug Development

The involvement of patients in shaping drug development offers invaluable first-hand information on their treatments.

Incorporating patient input into the design and the selection of endpoints in clinical trials ensures that studies address aspects that impact their quality of life, which can lead to higher enrolment rates. Patient-Reported Outcomes (PROs) should be designed to capture the impact of a disease and its treatment from the patient's perspective. After a drug is approved, patients continue to play a crucial role through post-market surveillance. Their feedback on the drug's effectiveness, side effects, and impact on daily life helps in identifying long-term benefits and risks. Regulatory agencies are increasingly engaging with patients to

understand their perspectives on risk-benefit analyses and regulatory decisions. Patients participate in advisory committees, public hearings and consultations, ensuring that their voices are considered in the regulatory process.

The trend towards patient-centric drug development is not only improving the quality of life for patients but also fostering innovation and efficiency in the healthcare industry. Several initiatives to train patients to provide their input will be introduced.

We are looking forward to welcoming you to meet our distinguished faculty and to discuss these advancements with colleagues.



A handwritten signature in black ink, appearing to read 'Thomas Szucs'.

Prof. Dr. Thomas D. Szucs
Director



A handwritten signature in black ink, appearing to read 'Annette Mollet'.

Dr. Annette Mollet
Head of Education & Training



A handwritten signature in black ink, appearing to read 'Nastazja Laskowski'.

Nastazja Laskowski
Course Director

Program Thursday, September 5, 2024

The Vital Role of Patients in Shaping Drug Development

Chair: Ingrid Klingmann

08:00

Registration for external participants

08.30 – 10:00

Involving the Patient in Medicines Development

Ingrid Klingmann, EFGCP and PharmaTrain, Belgium

Enabling the Involved Patient

Ivo Schauwecker, President EUPATI Switzerland, CH

10:00 – 10:30

Coffee Break

Co-Creation with Patients in Research and Development

Charlotta Norgaard, CEO of Patient in Research, Copenhagen

Enabling Patient Engagement Across the Medicine Lifecycle

Zack Pemberton-Whiteley, Novartis, Basel

12:00 – 13:00

Lunch

Patient Reported Outcomes in Data Sciences

Tom Willgoss, Roche, UK

Advocating Patient Involvement with Regulatory Authorities

Karen Cheng, Rare Disease Patient Advocate (MSU), Basel

14:30 – 14:45

Coffee Break

Patient Insight into the Value of a Product

Anke-Peggy Holtorf, Health Outcomes Strategies, Basel

Generating Patient-Centered Data and Insights

Mark Larkin, Vitaccess, Geneva

About Frontiers in Drug Development Seminars

ECPM offers one day seminars on new trends and developments in drug development science. These seminars provide the opportunity to integrate work and further education, to discuss with experts face-to-face and to build an international network. They take place on the fourth day of each of the six modules of the ECPM Diploma Course and are mandatory for students taking the Diploma Course. Additionally they are open to our alumni and other interested scientists and can be booked separately.

Learning Outcomes

Participants should learn more about various topics such as:

- Gain an understanding of the multifaceted and invaluable role of patients in shaping drug development
- Learn strategies for incorporating patients' perspectives for pharmaceutical companies, researchers, and regulatory bodies to develop more effective, safer, and patient-friendly treatments
- Explore real examples illustrating how patient-centric drug development is not only improving the quality of life for patients but also fostering innovation and efficiency in the healthcare industry.

Date and Venue

Thursday, September 5, 2024
University of Basel
Biozentrum
Spitalstrasse 41
4056 Basel
Switzerland

Registration

Via our homepage www.ecpm.ch or
www.ecpm.ch/frontiers-in-drug-development-s4

Deadline for Registration: August 28, 2024

Credits

Six workshops over a period of two years, which equal 1 ECTS credit. Accredited as continuing education with eight credits by the Swiss Society of Pharmaceutical Medicine (SGPM) and the Swiss Society of Pharmaceutical Professionals (SwAPP).

Fee

Course fee including certificate and electronic course material is CHF 580 for ECPM Alumni and CHF 480 for SwAPP/SGPM members. A reduced fee of CHF 210 applies to participants from academia and nonprofit organizations.

After registration you will receive an invoice. For registrations submitted after August 25, the fee must be paid on-site by credit card before the seminar.

Cancellation Policy

Refund of fee will be given if cancellation is received in writing before the deadline for registration, after this date no refund can be given. Speakers are subject to change without notice.

Seminar Organizer

This course is organized by the European Center of Pharmaceutical Medicine.

**Educating
Talents**
since 1460.

University of Basel
ECPM
Institute of Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland

www.ecpm.ch

